191 related articles for article (PubMed ID: 8560672)
1. Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6-9, 1995.
Urology; 1996 Jan; 47(1A Suppl):1-96. PubMed ID: 8560672
[No Abstract] [Full Text] [Related]
2. [Bicalutamide].
Kotake T
Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
[No Abstract] [Full Text] [Related]
3. Bicalutamide versus flutamide in combination therapy.
Labrie F; Candas B
Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411
[No Abstract] [Full Text] [Related]
4. New indication sought for bicalutamide.
Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
[No Abstract] [Full Text] [Related]
5. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
6. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
Sivko AV; Prokhorov AV
Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
[No Abstract] [Full Text] [Related]
7. Bicalutamide treatment for locally advanced prostate cancer.
Anderson J
Hosp Med; 2000 Sep; 61(9):660-3. PubMed ID: 11048610
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
9. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
Blackledge GR; Cockshott ID; Furr BJ
Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
[TBL] [Abstract][Full Text] [Related]
10. The clinical rationale for immediate androgen deprivation without estrogen deprivation.
Pitts WR
Clin Prostate Cancer; 2003 Sep; 2(2):127-8. PubMed ID: 15040875
[No Abstract] [Full Text] [Related]
11. Newer approaches to androgen deprivation therapy in prostate cancer.
Pitts WR
Urology; 2003 Apr; 61(4):882. PubMed ID: 12670593
[No Abstract] [Full Text] [Related]
12. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
13. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
14. Relative potency of bicalutamide (Casodex) and flutamide (Eulexin).
Kolvenbag GJ; Furr BJ
Urology; 1999 Jul; 54(1):194-7. PubMed ID: 10414753
[No Abstract] [Full Text] [Related]
15. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Garnick MB
BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
[No Abstract] [Full Text] [Related]
16. Bicalutamide ('Casodex') development: from theory to therapy.
Kolvenbag GJ; Furr BJ
Cancer J Sci Am; 1997; 3(4):192-203. PubMed ID: 9263623
[No Abstract] [Full Text] [Related]
17. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
18. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
19. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
Rusakov IG; Alekseev BIa
Urologiia; 2002; (5):23-6. PubMed ID: 12402771
[No Abstract] [Full Text] [Related]
20. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
[Next] [New Search]
